Literature DB >> 20568677

Potential impact of new WHO criteria for antiretroviral treatment for prevention of mother-to- child HIV transmission.

Louise Kuhn1, Grace M Aldrovandi, Moses Sinkala, Chipepo Kankasa, Mwiya Mwiya, Donald M Thea.   

Abstract

We reviewed the potential impact of new WHO criteria for antiretroviral therapy using data from 1025 HIV-infected women and infants followed for 24 months in Lusaka, Zambia. The new criteria require initiating therapy among 68% of pregnant women and, if fully effective, would prevent 92% of maternal deaths and 88% of perinatal and postnatal infections. Using CD4 cell count below 350 cells/microl, irrespective of clinical stage, is more efficient and stricter CD4 cutoffs would be counter productive.

Entities:  

Mesh:

Year:  2010        PMID: 20568677      PMCID: PMC2946203     

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  4 in total

1.  Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.

Authors:  Taha E Taha; Johnstone Kumwenda; Stephen R Cole; Donald R Hoover; George Kafulafula; Mary Glenn Fowler; Michael C Thigpen; Qing Li; Newton I Kumwenda; Lynne Mofenson
Journal:  J Infect Dis       Date:  2009-11-15       Impact factor: 5.226

2.  Effects of early, abrupt weaning on HIV-free survival of children in Zambia.

Authors:  Louise Kuhn; Grace M Aldrovandi; Moses Sinkala; Chipepo Kankasa; Katherine Semrau; Mwiya Mwiya; Prisca Kasonde; Nancy Scott; Cheswa Vwalika; Jan Walter; Marc Bulterys; Wei-Yann Tsai; Donald M Thea
Journal:  N Engl J Med       Date:  2008-06-04       Impact factor: 91.245

3.  Comparison of CD4 cell count, viral load, and other markers for the prediction of mortality among HIV-1-infected Kenyan pregnant women.

Authors:  Elizabeth R Brown; Phelgona Otieno; Dorothy A Mbori-Ngacha; Carey Farquhar; Elizabeth M Obimbo; Ruth Nduati; Julie Overbaugh; Grace C John-Stewart
Journal:  J Infect Dis       Date:  2009-05-01       Impact factor: 5.226

Review 4.  Universal antiretroviral therapy for pregnant and breast-feeding HIV-1-infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings.

Authors:  Renaud Becquet; Didier K Ekouevi; Elise Arrive; Jeffrey S A Stringer; Nicolas Meda; Marie-Laure Chaix; Jean-Marc Treluyer; Valériane Leroy; Christine Rouzioux; Stéphane Blanche; François Dabis
Journal:  Clin Infect Dis       Date:  2009-12-15       Impact factor: 9.079

  4 in total
  29 in total

Review 1.  Survival and health benefits of breastfeeding versus artificial feeding in infants of HIV-infected women: developing versus developed world.

Authors:  Louise Kuhn; Grace Aldrovandi
Journal:  Clin Perinatol       Date:  2010-12       Impact factor: 3.430

2.  Predictors of CD4 eligibility for antiretroviral therapy initiation among HIV-infected pregnant women in Lusaka, Zambia.

Authors:  Katherine C Liu; Jessica Mulindwa; Mark J Giganti; Nande B Putta; Namwinga Chintu; Benjamin H Chi; Jeffrey S A Stringer; Elizabeth M Stringer
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-15       Impact factor: 3.731

3.  Evolution of antiretroviral therapy services for HIV-infected pregnant women in Cape Town, South Africa.

Authors:  Landon Myer; Tamsin Phillips; Victoria Manuelli; James McIntyre; Linda-Gail Bekker; Elaine J Abrams
Journal:  J Acquir Immune Defic Syndr       Date:  2015-02-26       Impact factor: 3.731

4.  Antiretrovirals in pregnancy: a note of caution.

Authors:  D Heather Watts; Lynne M Mofenson
Journal:  J Infect Dis       Date:  2012-10-12       Impact factor: 5.226

5.  Optimal time on HAART for prevention of mother-to-child transmission of HIV.

Authors:  Carla J Chibwesha; Mark J Giganti; Nande Putta; Namwinga Chintu; Jessica Mulindwa; Benjamin J Dorton; Benjamin H Chi; Jeffrey S A Stringer; Elizabeth M Stringer
Journal:  J Acquir Immune Defic Syndr       Date:  2011-10-01       Impact factor: 3.731

6.  Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial.

Authors:  Hoosen M Coovadia; Elizabeth R Brown; Mary Glenn Fowler; Tsungai Chipato; Dhayendre Moodley; Karim Manji; Philippa Musoke; Lynda Stranix-Chibanda; Vani Chetty; Wafaie Fawzi; Clemensia Nakabiito; Lindiwe Msweli; Roderick Kisenge; Laura Guay; Anthony Mwatha; Diana J Lynn; Susan H Eshleman; Paul Richardson; Kathleen George; Philip Andrew; Lynne M Mofenson; Sheryl Zwerski; Yvonne Maldonado
Journal:  Lancet       Date:  2011-12-22       Impact factor: 79.321

7.  Field effectiveness of combination antiretroviral prophylaxis for the prevention of mother-to-child HIV transmission in rural Zambia.

Authors:  Matthew G Gartland; Namwinga T Chintu; Michelle S Li; Mwila K Lembalemba; Saziso N Mulenga; Maximillian Bweupe; Patrick Musonda; Elizabeth M Stringer; Jeffrey S A Stringer; Benjamin H Chi
Journal:  AIDS       Date:  2013-05-15       Impact factor: 4.177

8.  Individualizing the WHO HIV and infant feeding guidelines: optimal breastfeeding duration to maximize infant HIV-free survival.

Authors:  Andrea L Ciaranello; Valeriane Leroy; Asinath Rusibamayila; Kenneth A Freedberg; Roger Shapiro; Barbara Engelsmann; Shahin Lockman; Kathleen A Kelly; François Dabis; Rochelle P Walensky
Journal:  AIDS       Date:  2014-07       Impact factor: 4.177

9.  Maternal HIV infection influences the microbiome of HIV-uninfected infants.

Authors:  Jeffrey M Bender; Fan Li; Shoria Martelly; Erin Byrt; Vanessa Rouzier; Marguerite Leo; Nicole Tobin; Pia S Pannaraj; Helty Adisetiyo; Adrienne Rollie; Chintda Santiskulvong; Shaun Wang; Chloe Autran; Lars Bode; Daniel Fitzgerald; Louise Kuhn; Grace M Aldrovandi
Journal:  Sci Transl Med       Date:  2016-07-27       Impact factor: 17.956

Review 10.  Best strategies for global HCV eradication.

Authors:  Liesl M Hagan; Raymond F Schinazi
Journal:  Liver Int       Date:  2013-02       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.